NOT-AI-20-006: Clarification of Research Areas for NIAID RFA-AI-19-059: Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinical Trial Not Allowed)

Clarification of Research Areas for NIAID RFA-AI-19-059: Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinical Trial Not Allowed)

Notice Number: NOT-AI-20-006

Key Dates
Release Date: October 30, 2019

Related Announcements
RFA-AI-19-059

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to provide clarification of the specific areas of research interest described in RFA-AI-19-059: Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinical Trial Not Allowed) for potential applicants. The following changes have been made to RFA-AI-19-059 under the heading specified.

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Specific Areas of Research Interest

Current Text:

The FOA will only support activities associated with malaria parasites that cause human diseases, especially Plasmodium falciparum and P. vivax. Building on enhanced understanding of pre-erythrocytic malaria stage biology, the goal is to generate and preclinically validate novel immunogens or constructs, including sporozoite-based ones, or vaccine strategies that are superior to currently available ones, with the potential to overcome significant malaria vaccine challenges such as low level of vaccine efficacy, strain-specific protection, and/or short duration of protection.

Revised to read:

This FOA will only support research activities leading to vaccine discovery against human malaria, especially that caused by Plasmodium falciparum and P. vivax. Building on enhanced understanding of pre-erythrocytic malaria stage biology, the goal is to generate and preclinically validate novel immunogens or constructs, including sporozoite-based ones, or vaccine strategies that are superior to currently available ones, with the potential to overcome significant malaria vaccine challenges such as low level of vaccine efficacy, strain-specific protection, and/or short duration of protection.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Annie Mo, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3320
Email: moa@niaid.nih.gov